PetMed Express, Inc. (d/b/a PetMeds) is a leading nationwide direct-to-consumer pet pharmacy that provides a variety of products and services for pets, including prescription and non-prescription medications, food, supplements, supplies, and veterinary services. The company primarily caters to pet owners of dogs, cats, and horses, offering convenience, competitive pricing, fast delivery, and high-quality customer service. PetMeds markets its products through its websites, toll-free numbers, and mobile applications, making it a prominent player in the growing pet care industry.
- Non-Prescription Medications (OTC) and Supplies - Offers flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and other pet supplies.
- Prescription Medications (Rx) - Provides heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure treatments, and other specialty medications, including generic substitutes.
- Pet Foods - Sells premium pet foods, including veterinary prescription diets tailored to specific health needs.
- Other Products and Services - Includes telemedicine services through VetLive, enabling consultations, diagnoses, and prescriptions by board-certified veterinarians, as well as pet insurance offerings.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Sandra Y. Campos ExecutiveBoard | CEO and President | Board Member at Big Lots (NYSE: BIG), Fabric, PureRED; Operating Advisor at ShoulderUp Technology Acquisition Corp | Sandra Y. Campos joined PETS as CEO and President on April 29, 2024. She has extensive experience in e-commerce, retail, and brand management, previously serving as CEO of Diane von Furstenberg and Co-President of Women’s Apparel at Global Brands Group. She also focuses on unlocking shareholder value and integrating teams for growth. | View Report → |
Christine Chambers Executive | CFO, Treasurer, and Secretary | None | Christine Chambers has been CFO since August 2022, Treasurer since October 2022, and Secretary since May 2023. She has a strong financial background, having previously served as CFO at RealNetworks and held leadership roles at Rosetta Stone and the Bill & Melinda Gates Foundation. | |
Doug Krulik Executive | Chief Accounting Officer | None | Doug Krulik became the Chief Accounting Officer of PETS on August 19, 2024. He has extensive experience in accounting and finance, having held leadership roles at Etherio Holdings, Jushi Holdings, and Magic Leap. He is a Certified Public Accountant (CPA) and holds an MBA from the University of Miami. | |
Robyn D’Elia Executive | CFO | Board Member and Audit Committee Chair at itel | Robyn D’Elia joined PETS as CFO on September 16, 2024. She previously served as CFO at Odeko and Bed Bath & Beyond, where she oversaw significant revenue growth. She also founded RMD Advisory and advised on major transactions, including the sale of Aerie Pharmaceuticals. | |
Diana Garvis Purcel Board | Director | Board Member at Ocean Power Technologies (NYSE: OPTT) | Diana Garvis Purcel joined the PETS Board in April 2022 and serves as Chair of the Audit Committee. She is recognized as an "audit committee financial expert" and brings significant financial expertise to the company. She also serves on the board of Ocean Power Technologies. | |
Gian M. Fulgoni Board | Director | Board Member at Prophet, Fluree, Varcode, QualSights, HealthBridge; Senior Advisory Board Member for the Journal of Advertising Research; Venture Partner at 4490 Ventures | Gian M. Fulgoni has been a PETS Director since November 2002. He is a co-founder of comScore, Inc., and has extensive experience in marketing, advertising, and strategic decision-making. He serves on multiple boards and advisory roles, leveraging his expertise to guide PETS in evaluating marketing opportunities and addressing strategic challenges. | |
Justin Mennen Board | Director | Advisory Board Member at University of Kansas Business School; Governing Body Co-Chair at Global CIO Executive Summit of Evanta | Justin Mennen joined the PETS Board on June 3, 2024. He has over two decades of experience in digital technology transformation and previously held executive roles at Rite Aid Corporation, CompuCom Systems, and Estée Lauder Companies. He also serves in advisory roles at the University of Kansas and Evanta. | |
Leah Solivan Board | Director | Managing Director at Fuel Capital; Advisor to Monica + Andy; Venture Advisor to Screendoor Partners; Leadership roles in Young Presidents’ Organization (YPO) | Leah Solivan joined the PETS Board on June 24, 2024. She is the founder of TaskRabbit, which she scaled into an international business before its acquisition by IKEA. She is also a Managing Director at Fuel Capital and holds advisory and leadership roles in various organizations, including YPO. | |
Leslie C.G. Campbell Board | Chair of the Board | Board Member at Shapeways (NYSE: SHPW), PointClickCare, Riley Inc., Diligent, Bideawee Inc.; Advisory Board Member at Grapevine Solutions; Growth Advisory Board Member at Diligent | Leslie C.G. Campbell has been on the PETS Board since July 2018 and became Chair on January 5, 2024. She is recognized for her expertise in corporate governance, technology, and supply chain management. She also serves on multiple boards and advisory committees, contributing to her extensive leadership experience. |
- You have experienced three consecutive quarters of double-digit revenue declines ; besides pulling back on marketing spend, what are the other factors contributing to this softness, and how do you plan to reverse this trend?
- With reduced visits to veterinarians and pressure on customer spending , how are you adjusting your strategy to address reduced prescriptions and maintain customer compliance in your pharmacy segment?
- Given that you've eliminated 4,000 underperforming SKUs, which you say did not impact revenues , how do you ensure that SKU rationalization doesn't limit your ability to attract new customers and meet their product needs?
- Despite having a strong cash position of $50 million , why aren't you investing more heavily in marketing and promotions to drive revenue growth and new customer acquisition, especially in a competitive market?
- As you modernize your website and marketing to attract younger consumers but acknowledge that this will take time and multiple touchpoints , how do you plan to bridge the revenue gap and maintain growth during this transition period?
Research analysts who have asked questions during PETMED EXPRESS earnings calls.
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
PetCareRx, Inc. | 2024 | PetMed Express acquired PetCareRx through a cash-funded merger for $36.1 million (with $26.7 million in goodwill) to become its wholly-owned subsidiary, expanding its product catalog (especially non‐medication products), distribution capabilities, and customer base by adding about 286,000 customers along with key intangible assets and a strong membership program. |
Recent press releases and 8-K filings for PETS.
- PetMed Express, Inc. (PETS) filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, on October 14, 2025.
- For fiscal 2025, the company reported net sales of $227.0 million and a net loss of $6.3 million. The net loss was higher than previously estimated, primarily due to a $1.2 million non-cash impairment charge for intangible assets.
- The reported net sales were below the preliminary estimated range, mainly due to a restatement of promotional sales reimbursements from revenues to cost of sales, which did not impact net income.
- As of March 31, 2025, PetMeds held $54.7 million in cash and had no debt.
- The company plans to file its Quarterly Reports on Form 10-Q for the first quarter ended June 30, 2025, and the second quarter ended September 30, 2025, as soon as practicable to resume its normal quarterly reporting schedule.
- PetMed Express, Inc. filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, on October 14, 2025.
- For fiscal 2025, the company reported net sales of $227.0 million, which was below the preliminary estimated range, and a net loss of $6.3 million, exceeding the preliminary estimated range primarily due to a $1.2 million non-cash impairment charge for intangible assets.
- As of March 31, 2025, PetMed Express held $54.7 million in cash and had no debt.
- The company plans to file its Quarterly Reports on Form 10-Q for the first and second quarters of fiscal 2025 as soon as practicable to resume its normal quarterly reporting schedule.
- PetMed Express's share price has declined by approximately 26% since June 16, 2025, following announcements of filing delays and other company problems.
- On October 7, 2025, the company revealed that its financial statements for the years ended March 31, 2024 and 2023, along with several interim quarters, "should no longer be relied upon" due to overstated net sales and accelerated revenue recognition.
- The CEO, CFO, and Audit Committee chair departed or resigned between July and August 2025, concurrent with an internal investigation triggered by a whistleblower complaint.
- As of October 9, 2025, PetMed has not filed its annual financial statements for the year ended March 31, 2025, nor its most recent quarterly reports.
- PetMed Express, Inc. (PETS) received a notice from Nasdaq on August 20, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1).
- The non-compliance is due to the company's delay in filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
- The company has until September 1, 2025, to submit a plan to regain compliance, with a potential exception period extending until December 29, 2025.
- The notice has no immediate effect on the listing of the company's common stock on Nasdaq.
- Bragar Eagel & Squire, P.C. is investigating potential claims against PetMed Express, Inc..
- PetMed Express, Inc. delayed its fourth quarter and fiscal year 2025 earnings release and conference call, which was originally scheduled for June 10, 2025.
- The company stated the delay is due to requiring additional time to complete the year-end audit process.
- Following this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.
- Bragar Eagel & Squire, P.C. is investigating PetMed Express, Inc. (PETS) for potential violations of federal securities laws and/or unlawful business practices.
- This investigation follows PetMed's June 10, 2025, announcement of a delay in its Q4 and fiscal year 2025 earnings release and conference call, citing the need for additional time to complete the year-end audit process.
- Following this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.
- PetMed Express, Inc. (PetMeds) received a notice from Nasdaq on July 2, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
- The notice has no immediate effect on the listing or trading of PetMeds' common stock on Nasdaq.
- PetMeds must submit a plan to regain compliance within 60 calendar days, or by September 1, 2025. Nasdaq may grant an exception for up to 180 calendar days from the Form 10-K due date, or until December 29, 2025, for the Company to regain compliance.
- The Company is working diligently to complete and file the Form 10-K as soon as practicable to regain compliance.
- PetMed Express, Inc. (PETS) will be unable to file its 2025 Form 10-K for the fiscal year ended March 31, 2025, by the July 1, 2025, extension deadline.
- The delay is due to an ongoing Audit Committee investigation into anonymous whistleblower reports.
- The investigation concerns the timing of revenue recognition for certain autoship orders in fiscal Q4 2025, a $50 coupon promotion's potential impact on key-performance indicators (KPIs) regarding new customers in fiscal Q4 2025, and the company's culture and control environment.
- Based on evidence gathered to date, the company does not currently expect the investigation to have a material impact on its previously announced preliminary financial results for Q4 and FY 2025 or previously filed financial results.
- PetMed Express estimates Q4 FY2025 net sales of $51.1 M–$53.1 M, down from $66.5 M in Q4 FY2024, and a net loss of $9.9 M–$10.4 M versus a $5.0 M loss in the prior year period.
- For FY 2025, the company expects net sales of $231.6 M–$233.6 M (FY 2024: $281.1 M) and a net loss of $4.5 M–$5.0 M (FY 2024: $7.5 M), reflecting an $8.7 M stock-compensation reversal and a $6.4 M deferred tax valuation allowance.
- As of March 31, 2025, PetMed Express held $54.7 M in cash and no debt.
- The company filed a Form 12b-25 for a late filing of its FY 2025 Form 10-K and expects to file by July 1, 2025.